References
- Bladé J, Fernández de Larrea C, Rosiñol L, et al. Soft-tissue plasmacytomas in multiple myeloma: incidence, mechanisms of extramedullary spread, and treatment approach. J Clin Oncol 2011;29: 3805–3812.
- Hayes DW, Bennett WA, Heck FJ. Extramedullary lesions in multiple myeloma; review of literature and pathologic studies. AMA Arch Pathol 1952;53:262–272.
- Papanikolaou X, Repousis P, Tzenou T, et al. Incidence, clinical features, laboratory findings and outcome of patients with multiple myeloma presenting extramedullary relapse. Leuk Lymphoma 2013; 54:1459–1464.
- Varettoni M, Corso A, Pica G, et al. Incidence, presenting features and outcome of extramedullary disease in multiple myeloma: a longitudinal study on 1003 consecutive patients. Ann Oncol 2010; 21:325–330.
- Wu P, Davies F, Boyd K, et al. The impact of extramedullary disease at presentation in the outcome of myeloma. Leuk Lymphoma 2009;50:230–235.
- Pérez-Simón JA, Sureda A, Fernández-Aviles F, et al. Reduced-intensity conditioning allogeneic transplantation is associated with a high incidence of extramedullary relapses in multiple myeloma patients. Leukemia 2006;20:542–545.
- Keats JJ, Chesi M, Egan JB, et al. Clonal competition with alternating dominance in multiple myeloma. Blood 2012;120: 1067–1076.
- Magrangeas F, Avet-Loiseau H, Gouraud W, et al. Minor clone provides a reservoir for relapse in multiple myeloma. Leukemia 2013;27:473–481.
- Rosinol L, Cibeira MT, Blade J, et al. Extramedullary multiple myeloma escapes the effect of thalidomide. Haematologica 2004; 89:832–836.
- Patriarca F, Prosdocimo S, Tomadini V, et al. Efficacy of bortezomib therapy for extramedullary relapse of myeloma after autologous and non-myeloablative allogeneic transplantation. Haematologica 2005; 90:278–279.
- Paubelle E, Coppo P, Garderet L, et al. Complete remission with bortezomib on plasmacytomas in an end-stage patient with refractory myeloma who failed all other therapies including hematopoietic stem cell transplantation. Possible enhancement of graft-vs-tumor effect. Leukemia 2005;19:702–704.